Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.

Date publication

janvier 2025

Journal

JTO clinical and research reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Rolfo C, Greillier L, Veillon R, Badin F, Ghiringhelli F, Isambert N, Paulus A, Chaudhary SP, Vugmeyster Y, Sato M, Hiret S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39717667

Résumé

In a phase 1 study, bintrafusp alfa was found to have an encouraging clinical activity in patients with previously treated advanced NSCLC. This study evaluated the safety and efficacy of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC regardless of the programmed death-ligand 1 (PD-L1) expression status.

Mots clés

Bifunctional, Bintrafusp alfa, Non–small cell lung cancer, Stage IV, TGF-β

Référence

JTO Clin Res Rep. 2025 01;6(1):100748